IONS Stock Recent News

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 10:15 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Okay. Thank you, everyone, for being here.

Ionis surges to a 52-week high after Tryngolza shows strong triglyceride reductions and cuts acute pancreatitis risk by 85% in late-stage studies.

Ionis Pharmaceuticals' stock jumped 35% on September 2, 2025, after positive late-stage clinical trial results for olezarsen, a therapy for severe hypertriglyceridemia (sHTG). Investor enthusiasm is anchored in olezarsen's estimated peak sales potential of $2.5 billion—a figure that towers over Ionis' current twelve-month revenue of $944 million.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025 Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 A live webcast of these presentations can be accessed on the Investors &a.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Positive CORE and CORE2 Topline Results Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Director Sotirios Tsimikas - Senior Vice President of Global Cardiovascular Development Kyle Jenne - Executive VP & Chief Global Product Strategy Officer Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Yanan Zhu - Wells Fargo Securities, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Jason Gerberry - BofA Securities, Research Division Luca Issi - RBC Capital Markets, Research Division Michael Ulz - Morgan Stanley, Research Division Ike Lee Yaron Werber - TD Cowen, Research Division Jacob Roberge - William Blair & Company L.L.C.

Ionis Pharmaceuticals stock jumped 31% on Tuesday hitting a new 52-week high after breakthrough news that lit up investor interest and boosted confidence across the biotech sector.

Ionis Pharmaceuticals, Inc. IONS on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG).

Ionis Pharmaceuticals' shares surged on Tuesday before the bell after the drugmaker said its experimental treatment significantly reduced levels of blood fats called triglycerides and reduced pancreatitis risk in two large late-stage studies.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG). In the studies, olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% and a highly statistically significant reduction in acute pancreatitis events of 85% with favorable safety and tolerability.

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pick-and-shovel' suppliers like Repligen, Illumina, and Twist Biosciences, which offer more stable financial prospects.